Contact Information
Identifies risk of developing 11 hereditary cancers
Identifies risk of breast cancer recurrence to inform treatment strategies
Identifies BRCA1/2 mutations to inform treatment strategies
Identifies HRD status to inform treatment strategies
Identifies prostate cancer aggressiveness to inform treatment strategies
Identifies at-risk couples for a pregnancy affected by inherited conditions
Identifies risk of chromosomal conditions for expectant parents
Identifies how genes affect outcomes with certain mental health medications
© 2022 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.